Related Experiment Video

Updated: May 21, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

Interleukin-6 signaling pathway in targeted therapy for cancer

Yuqi Guo1, Feng Xu, TianJian Lu

  • 1The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China.

Cancer Treatment Reviews
|June 2, 2012
PubMed

Insights

Interleukin-6 (IL-6) drives tumor progression by promoting growth and resistance. Targeting IL-6 signaling with antibody therapy offers a promising strategy for various cancers, showing good patient tolerance.

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Interleukin-6 (IL-6) is a cytokine crucial for immune responses and cellular processes, including tumor cell growth and differentiation.
  • IL-6 signaling, particularly through Signal Transducer and Activator of Transcription 3 (Stat3), is implicated in various malignancies.
  • Overexpression of IL-6 is linked to tumor progression, inhibiting apoptosis, promoting angiogenesis, and conferring drug resistance.

Purpose of the Study:

  • To review the current understanding of the IL-6 signaling pathway in cancer.
  • To discuss the potential of anti-IL-6 therapy as a cancer treatment strategy.

Main Methods:

  • Literature review of studies on IL-6 signaling in cancer.
  • Analysis of clinical data regarding IL-6 serum concentrations and patient outcomes.
  • Evaluation of preliminary clinical evidence for antibody-targeted IL-6 therapy.

Main Results:

  • Elevated IL-6 serum levels correlate with advanced cancer stages and reduced survival across multiple cancer types.
  • IL-6 blockade is a viable therapeutic strategy for cancers with pathological IL-6 overproduction.
  • Antibody-targeted IL-6 therapy has demonstrated good tolerability in clinical trials.

Conclusions:

  • IL-6 plays a significant role in cancer development and progression.
  • Targeting IL-6 signaling represents a promising therapeutic avenue for cancer treatment.
  • Further research and clinical application of anti-IL-6 therapies are warranted.

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification10:21

Primary Sjogren's Syndrome Associated with Lung Adenocarcinoma: Probing the Potential Common Pathogenic Mechanisms and Experimental Verification

Published on: September 20, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...